Here we report that treatment of prostate cancer cells with M-110 or a structurally unrelated PIM kinase inhibitor SGI-1776 increases the expression of MIG6 RNA and protein and inhibits EGF induced activation of the EGFR and the downstream ERK MAPkinase pathway. This evidence concerns the gene ERRFI1 and prostate cancer.